Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...
The Print on MSN1d
PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAYReport commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...
The hospital has introduced the Ion robotic system, a groundbreaking tool designed to improve the detection of small lung ...
Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory ...
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and ...
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.
Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...
Ochsner Lafayette General Medical Center performed its first procedure with the Ion robotic-assisted bronchoscopy system; ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback